The rising incidence of cancer, diabetes, rare genetic diseases, and other chronic conditions is strengthening demand for cell and gene therapies in Mexico. Gene therapies are gaining attention for inherited disorders such as hemophilia, sickle cell anemia, and lysosomal storage diseases, while ... The rising incidence of cancer, diabetes, rare genetic diseases, and other chronic conditions is strengthening demand for cell and gene therapies in Mexico. Gene therapies are gaining attention for inherited disorders such as hemophilia, sickle cell anemia, and lysosomal storage diseases, while stem cell and chimeric antigen receptor T-cell (CAR-T) therapies are advancing oncology treatment. Mexico’s cell and gene therapy sector is gaining momentum amid rising disease burdens, expanding biotech infrastructure, streamlined approvals and... Therapy type: Cell therapy, including pluripotent stem cells, cancer stem cells, adult stem cells, T-cells, natural killer cells, and other non-stem-cell therapies; and gene therapy. Indication: Cardiovascular diseases, oncology disorders, genetic disorders, infectious diseases, neurological disorders, and other conditions. Key Topics Covered: 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Mexico Cell and Gene Therapy Market - Introduction 4.1 Overview 4.2 Market Dynamics 4.3 Industry Trends 4.4 Competitive Intelligence 5 Mexico Cell and Gene Therapy Market Landscape 5.1 Historical and Current Market Trends (2020-2025) 5.2 Market Forecast (2026-2034) 6 Mexico Cell and Gene Therapy Market - Breakup by

Recent research highlights the potential of biologic therapies in mitigating neurodegeneration associated with lysosomal storage diseases. This study contributes to the growing body of evidence supporting innovative treatment approaches for these complex conditions.

A natural history study is a preplanned ... of the disease. Should the data demonstrate compelling clinical activity, Polaryx may pursue an expedited approval pathway. For more information about the SOTERIA trial, please visit https://clinicaltrials.gov/study/NCT07740512. ... Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for rare orphan lysosomal ... A natural history study is a preplanned observational study intended to track the course of the disease. Should the data demonstrate compelling clinical activity, Polaryx may pursue an expedited approval pathway. For more information about the SOTERIA trial, please visit https://clinicaltrials.gov/study/NCT07740512. ... Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for rare orphan lysosomal storage disorders (LSDs). Charlton is a board-certified pediatric endocrinologist with nearly two decades of leadership in rare disease and pediatric drug development across the full development lifecycle. According to Polaryx Therapeutics, his appointment is intended to strengthen clinical leadership and execution ahead of the planned SOTERIA Phase 2 trial of PLX-200, expected to initiate in Q4 2026. For investors, it matters because diagnosis, ongoing therapy, newborn screening and potential new drugs or gene therapies can drive medical spending, regulatory approvals and market opportunity in endocrinology and rare disease care. ... A pediatric endocrinologist is a medical specialist who diagnoses and treats hormone-related conditions in infants, children and adolescents, such as growth disorders, diabetes, thyroid problems and delayed puberty. Their expertise matters to investors when companies report clinical trial results, regulatory reviews, advisory-board appointments or guidance about pediatric use, because these doctors assess safety, dosing and effectiveness for younger patients—like a specialist mechanic for a particular class of engines. I look forward to bringing my experience to the SOTERIA trial and being of service to pediatric patients and families.” “Will has extensive experience serving as a Chief Medical Officer and leading rare disease clinical trials, coupled with his background as a pediatrician and passion for developing patient-friendly therapies, making him an excellent fit to lead our SOTERIA trial,” said Alex Yang, Polaryx Therapeutics’ Chief Executive Officer.

-- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes inFabry disease and alpha-mannosidosis -- -- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes inFabry disease and alpha-mannosidosis -- -- Rooted in patient voice and scientific rigor, this research reflects Chiesi’s long-standing role in advancing science for the lysosomal storage disorders community -- PARMA, Italy, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced presentations at the Society of Inborn Errors of Metabolism (SSIEM) 2026 Annual Symposium, held August 25-28, 2026, in Helsinki, Finland. The condition affects both males and females and can present from childhood through adulthood, often with delayed diagnosis or misdiagnosis. While Fabry disease is rare, early detection and access to appropriate treatment - such as enzyme replacement therapy or pharmacological chaperone therapy - are critical in managing symptoms and slowing disease progression. Chiesi-led presentations include long-term Phase 3 data from the F60/BRILLIANCE trial, patient-reported outcomes from a cross-sectional survey in untreated Fabry disease, and research exploring earlier diagnosis and genotype-phenotype relationships in alpha-mannosidosis. Independent studies supported by Chiesi examine real-world clinical experience, disease biology, biomarkers, and newborn screening. "From new tools that could help identify diagnosis earlier to long-term data on treatment outcomes, this research is united by a single goal: better understanding the experiences of people living with rare diseases and using those insights to help inform care. We're proud to have shared these findings with the broader scientific community and remain devoted to advancing solutions that make a meaningful difference.” ... By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy. "This body of evidence spans long-term clinical trial data, real-world outcomes, and new biomarker research, contributing to a more comprehensive understanding of disease progression and unmet needs across the care journey,” said Alessio Amadasi, Vice President, Medical Affairs EU & International, Chiesi Global Rare Diseases.

A natural history study is a preplanned ... of the disease. Should the data demonstrate compelling clinical activity, Polaryx may pursue an expedited approval pathway. For more information about the SOTERIA trial, please visit https://clinicaltrials.gov/study/NCT07740512. ... Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for rare orphan lysosomal ... A natural history study is a preplanned observational study intended to track the course of the disease. Should the data demonstrate compelling clinical activity, Polaryx may pursue an expedited approval pathway. For more information about the SOTERIA trial, please visit https://clinicaltrials.gov/study/NCT07740512. ... Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for rare orphan lysosomal storage disorders (LSDs). Company on track to initiate SOTERIA trial in the second half of 2026 · Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four planned indication · PARAMUS, NJ, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (“LSDs”), today provided an operational readiness update for SOTERIA, its Phase 2 basket trial evaluating lead candidate PLX-200 across four rare pediatric LSDs. Company on track to initiate SOTERIA trial in the second half of 2026 Clinical development activities advancing following FDA authorization, CRO... Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial · PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying...